证券代码：301290 证券简称：东星医疗 公告编号：2023-061 江苏东星智慧医疗科技股份有限公司 第三届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 经审核，监事会认为：公司 2023 年半年度募集资金的存放与使用符合中国 证券监督管理委员会、深圳证券交易所对募集资金存放和使用的相关要求，不存 在违规使用募集资金的行为，亦不存在改变或者变相改变募集资金投向和损害股 东利益的情形。 具体内容详见公司同日于巨潮资讯网（www.cninfo.com.cn)披露的《2023 年半年度募集资金存放与使用情况的专项报告》。 一、监事会会议召开情况 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）第三届监事会 第十一次会议于 2023 年 8 月 24 日在公司会议室以现场方式召开。本次会议通知 已于 2023 年 8 月 14 日通过邮件的方式送达全体监事。本次会议由监事会主席李 妍彦主持，会议应出席监事 3 人，实际出席监事 3 人。公司董事会秘书列席会议。 本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公司章程 ...

证券代码：301290 证券简称：东星医疗 公告编号：2023-059 江苏东星智慧医疗科技股份有限公司 关于公司全资子公司收购常州昶恒精密模具科技有限公司 51% 股权并完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1、姚超杰，男，1980 年 2 月出生，中国国籍，住址为广东省高州市镇江镇 金村甘村；身份证号:440981198002******,无境外永久居留权。 2、梁昌红，男，1988 年 5 月出生，中国国籍，住址为安徽省六安市金安区 马头镇十字路村立新组；身份证号：342401198805******,无境外永久居留权。 3、朱荣浩，男，1984 年 1 月出生，中国国籍，住址为广东省高州市镇江镇 含屋宁福山村；身份证号：440981198401******，无境外永久居留权。 （二）交易对手方情况说明 一、对外投资概述 江苏东星智慧医疗科技股份有限公司(以下简称"公司"或"东星医疗")召 开总经理办公会，同意公司全资子公司江苏孜航精密五金有限公司（以下 简称"孜航精密"）与姚超杰、梁昌红、朱荣浩（以下统称"交易对手方" ...

投资者关系活动记录表 | --- | --- | --- | |----------------------------|------------------------------------------------------------|--------------------------------------------------------| | 证券代码： | 301290 | 证券简称：东星医疗 | | | | 编号：2023-005 | | | √ 特定对象调研 | □ 分析师会议 | | 投资者关系活动类别 | □ 媒体采访 □□ 新闻发布会 □□ 现场参观 | 业绩说明会 路演活动 | | | □ 其他 （请文字说明其他活动内容） | | | | 协力律师事务所：张内 | | | | 千寻资产管理有限公司：张云舟 | | | | 上海昶元资产：陈汝流 | | | | 毅行资本：褚嘉斌 | | | 参与单位名称及人员姓名 | 俾斯麦资本：高杰、万佳海常州大学：姚惠泽常州泰富集团：陆群 | | | | | 个人投资者：陆文贤、梁荣军、陈学祥、姚曙浩、邵金成、盛 | | | 为农 | | | ...

| 投资者关系活动 | □特定对象调研 □ 分析师会议 | | --- | --- | | 类别 | 媒体采访 业绩说明会 □ √ | | | 路演活动 □ 新闻发布会 □ | | | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2023 年 5 月 9 日 (周二) 下午 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、东星医疗 董事长万世平 | | 员姓名 | 2、东星医疗 董事、副总经理、财务总监、董事会秘书龚爱琴 | | | 3、保荐代表人庄晨 | | | 4、东星医疗 独立董事徐光华 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： 1、请问募投项目大概什么时间能验收，原计划产能是多少？对 | | | 于开阔新的市场与保持老客户，有做哪方面努力！在国外方面， | | 投资者关系活动 | 有怎样的营销策略？ ...

Financial Performance - The company's operating revenue for 2022 was approximately ¥442.1 million, a decrease of 0.99% compared to ¥446.5 million in 2021[21]. - The net profit attributable to shareholders for 2022 was approximately ¥102.5 million, down 7.03% from ¥110.3 million in 2021[21]. - The net cash flow from operating activities decreased by 42.10% to approximately ¥94.6 million in 2022, compared to ¥163.4 million in 2021[21]. - The total assets at the end of 2022 reached approximately ¥2.38 billion, an increase of 91.56% from ¥1.24 billion at the end of 2021[21]. - The net assets attributable to shareholders increased by 101.74% to approximately ¥2.19 billion at the end of 2022, compared to ¥1.09 billion at the end of 2021[21]. - The basic earnings per share for 2022 was ¥1.33, a decrease of 9.52% from ¥1.47 in 2021[21]. - The company reported a total of ¥7.99 million in non-recurring gains and losses for 2022, compared to ¥6.93 million in 2021[27]. - The company achieved a total operating revenue of CNY 442.10 million in 2022, a decrease of 0.99% compared to the previous year[49]. - The medical device sector contributed CNY 314.07 million, accounting for 71.04% of total revenue, reflecting a decline of 4.78% year-on-year[50]. - The core product, surgical staplers, generated CNY 183.27 million, representing 41.46% of total revenue, with an 11.03% decrease from the previous year[50]. - The company reported a gross profit margin of 40.46% for the other industry segment, with a revenue of CNY 128.03 million[53]. - The total sales amount from the top five customers accounted for 27.95% of the annual sales, totaling CNY 123.56 million[58]. - The total procurement amount from the top five suppliers was CNY 38.94 million, representing 26.57% of the annual procurement total[59]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 5 RMB per 10 shares to all shareholders, based on a total of 100,173,334 shares[4]. - The cash dividend accounted for 100% of the total profit distribution amount[143]. - The company paid a total of CNY 3.767 million in salaries to 10 directors, supervisors, and senior management personnel in 2022, including CNY 288,000 in independent director allowances[128]. - The remuneration for directors and supervisors is determined by the shareholders' meeting, while senior management remuneration is decided by the board of directors[126]. - The total pre-tax compensation for the board members amounted to 376.70 million[129]. - The company has committed to maintaining a dividend payout ratio of 30% of net profits for the next three years[162]. Governance and Compliance - The report emphasizes the importance of risk awareness regarding future plans and forecasts, indicating potential operational risks and corresponding countermeasures[4]. - The company has confirmed that all board members attended the meeting to review the annual report, ensuring governance transparency[4]. - The financial report is guaranteed to be true, accurate, and complete by the company's responsible personnel, including the chairman and accounting heads[3]. - The report mentions the importance of compliance with regulatory standards, such as CE and FDA certifications for medical devices[14]. - The company maintains complete independence from its controlling shareholders in terms of assets, personnel, finance, and operations, ensuring no conflicts of interest or unfair transactions[110]. - The company has established an independent financial department with dedicated accounting personnel, ensuring autonomous financial decision-making and management[111]. - The company has a robust internal governance structure, including a general meeting, board of directors, and supervisory board, functioning independently from its controlling shareholders[112]. - The company complies with all relevant laws and regulations regarding corporate governance, ensuring no significant discrepancies with regulatory requirements[109]. - The company has implemented a rigorous internal control system to mitigate various risks and enhance operational efficiency[106]. Research and Development - The company is developing a self-cleaning puncture device to reduce contamination during endoscopic procedures, enhancing product line and market competitiveness[60]. - A new disposable circular cutting anastomosis device is under development, aimed at reducing patient trauma and postoperative complications[60]. - The company is working on absorbable tissue clips that will fully absorb within 180 days post-surgery, addressing the limitations of traditional metal clips[60]. - The company has developed a new type of absorbable suture for laparoscopic components, which reduces the rate of suture formation defects and improves hemostatic performance[61]. - The company’s R&D investment amounted to ¥24,212,546.29 in 2022, representing 5.48% of total revenue, an increase from 4.63% in 2021[63]. - The number of R&D personnel increased to 94 in 2022, a growth of 4.44% compared to 90 in 2021[63]. - The company is focusing on developing industry-leading products such as electric laparoscopic staplers and ultrasonic knives, as well as improving the quality of its components[101]. Market Expansion and Strategy - The company plans to continue expanding its market presence and product offerings in the medical device sector[30]. - The global medical device market was approximately $427.8 billion in 2018 and is expected to reach $594.5 billion by 2024, indicating a growth trend[31]. - The company aims to become a leading domestic enterprise in minimally invasive surgery, focusing on enhancing product quality and market share[94]. - Future strategic plans include establishing a leading R&D center for surgical instruments and developing innovative products such as electric endoscopic staplers and surgical navigation systems[94]. - The company plans to expand its market presence by entering three new provinces in 2023, aiming for a 20% increase in user acquisition[162]. - The company is exploring potential acquisitions to enhance its market position, with a budget of 300 million RMB allocated for this purpose[161]. - The company is exploring potential mergers and acquisitions to strengthen its competitive position in the healthcare sector[166]. Operational Efficiency and Cost Management - The company aims to improve operational efficiency, targeting a 10% reduction in costs by the end of 2023[161]. - The company is implementing new strategies to improve operational efficiency, aiming to reduce costs by 10% in the upcoming fiscal year[166]. - The company has a strong market position as the largest agent for Mingji Sanfeng in mainland China, with significant annual sales volume in medical devices[38]. - The company employs a production model based on "sales-driven production" and maintains appropriate inventory levels to respond to customer orders effectively[40]. - The company utilizes a dual-channel sales model, including traditional distribution and direct sales, to optimize market reach and customer service[42]. Risk Management - The company is aware of the rapid technological advancements in the medical device industry and is focused on timely product updates to maintain market recognition[100]. - The company faces risks related to price declines due to "volume-based procurement," which may impact sales revenue and profit margins if not managed effectively[99]. - The company is prepared to address regulatory risks by maintaining compliance with national medical device regulations and ensuring product quality[103]. Employee and Labor Relations - Employee rights are prioritized through talent development strategies and compliance with labor laws, fostering a harmonious labor relationship[154]. - The company invested in employee training programs to enhance skills and professional development[139]. - The total number of employees at the end of the reporting period was 697, with 639 from major subsidiaries and 58 from the parent company[137]. Environmental and Social Responsibility - The company strictly adheres to environmental protection laws and has not faced any administrative penalties during the reporting period[153]. - Environmental protection and sustainable development are integral to the company's strategy, promoting green practices and raising employee awareness[155]. - The company has not engaged in poverty alleviation or rural revitalization efforts during the reporting period[156].

江苏东星智慧医疗科技股份有限公司 2023 年第一季度报告 证券代码：301290 证券简称：东星医疗 公告编号：2023-032 江苏东星智慧医疗科技股份有限公司 2023 年第一季度报告 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经过审计 □是 否 1 江苏东星智慧医疗科技股份有限公司 2023 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业收入（元） | 84,021,879.90 | 92,315,590.60 | -8.98% | ...

证券代码：301290 证券简称：东星医疗 公告编号：2023-031 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 欢迎广大投资者积极参与本次网上说明会。 江苏东星智慧医疗科技股份有限公司 关于举行2022年度网上业绩说明会的公告 江苏东星智慧医疗科技股份有限公司(以下简称"公司")于2023年4月25 日披露了《2022年年度报告》全文及其摘要。为便于广大投资者更深入全面地了 解公司情况，进一步加强与投资者的沟通，做好投资者关系管理工作，公司拟定 于2023年5月9日(星期二)15:00-17:00在全景网举行2022年度业绩说明会，现将 有关事项通知如下： 本次年度业绩说明会将采用网络远程的方式举行，投资者可登陆"全景·路演天 下"(http://rs.p5w.net)参与本次年度业绩说明会。 出席本次业绩说明会的人员有：公司董事长万世平先生，副总经理、董事会秘 书、财务总监龚爱琴女士，独立董事徐光华先生，保荐代表人庄晨先生。 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资 ...